Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Cornea. 2013 May;32(5):667–673. doi: 10.1097/ICO.0b013e318277ac74

Table 2.

Treatment regimen versus visual outcomes.

Nata Only
(N=26)
Nata+Azoles
(N=11)
Nata+Others
(N=4)
Others
(N=7)
P-value
Mean Initial BCVA 0.66 (0.73)
20/91
1.27 (0.99)
20/372
0.54 (0.38)
20/69
0.92 (0.99)
20/166
0.20*
Mean Follow up BCVA 0.24 (0.46)
20/35
1.74 (1.24)
20/1099
0.11 (0.08)
20/26
0.73 (1.12)
20/107
<0.001*
Mean BCVA improvement 0.43 (0.67) −0.47 (1.23) 0.43 (0.31) 0.32 (0.42) 0.03*
Initial BCVA Better than or equal to 20/40 11 (42.3%) 1 (9.1%) 2 (50%) 2 (28.6%) 0.22**
Follow up BCVA Better than or equal to 20/40 22 (88%) 3 (27.3%) 4 (100%) 4 (66.7%) 0.001**
BCVA improve 2 or more lines 14 (56%) 2 (18.2%) 4 (100%) 3 (50%) 0.032**
*

Analysis of Variance (ANOVA) was performed.

**

Chi-Square Test

Mean follow up BCVA was worse than mean initial BCVA.